Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) Price Target at $50.08

Pharvaris N.V. (NASDAQ:PHVS) has earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $50.0833.

A number of equities analysts have issued reports on the company. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $34.94 on Thursday. Pharvaris has a 1 year low of $19.12 and a 1 year high of $36.60. The business’s 50-day moving average is $32.16 and its 200-day moving average is $28.99. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -10.99 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. Analysts anticipate that Pharvaris will post -3.2 EPS for the current year.

Insider Activity

In other news, Director Robert Glassman sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total transaction of $298,200.00. Following the transaction, the director owned 10,500 shares of the company’s stock, valued at $313,110. This represents a 48.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Peng Lu sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the sale, the insider owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. This represents a 18.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 303,356 shares of company stock valued at $9,746,065. Corporate insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its holdings in shares of Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after buying an additional 520 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Pharvaris during the 4th quarter valued at about $35,000. Public Employees Retirement System of Ohio increased its holdings in Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.